Cardiology Today


The following articles appeared in the print edition of CARDIOLOGY TODAY.

Table of Contents
Cover Story

Nonobstructive CAD: Recognition needed, treatment options sought

FDA News

FDA approves left atrial appendage closure device

FDA requires labeling changes for testosterone therapies to reflect CV risk

In the Journals

Musculoskeletal pain common among health care workers participating in interventional procedures

Frequent sauna use associated with reduced risk for CV-related, all-cause mortality in men

Many with AF qualify for oral anticoagulation therapy under new guidelines

Low systolic BP, multiple BP medications increase mortality risk in frail elderly adults

Stress could be factor for poor MI recovery in young women

Advanced age, comorbidities may weaken ICD survival benefit

Patients with high genetic risk for CHD benefit most from statin therapy

Concomitant NSAIDs with antithrombotic therapy after MI worsen outcomes

Circulating neprilysin may predict CV death, HF hospitalization

Industry News

New recommendations for managing high BP anticipated in 2016

Meet the Board

Nathaniel Reichek, MD: A pioneer in the development of cardiac MRI

Meeting News Coverage

Practice changes can reduce radiation exposure in pediatric cardiac cath lab

CADISS: No difference in treatment with antiplatelets, anticoagulants after cervical artery dissection

Plant-based diet lowers risk for CVD mortality

Vasoactive-ventilation-renal score predicts outcomes after pediatric cardiac surgery

PEGASUS–TIMI 54: Ticagrelor linked with better outcomes in patients at least 1 year after MI

Automated text messaging may improve CV medication adherence

Third-generation balloon-expandable TAVR system linked to lower death, stroke rates

TOTAL: Manual thrombectomy with PCI does not improve outcomes, increases short-term stroke rate

PROMISE: CTA, functional testing associated with similar outcomes in patients with suspected CAD

SCOT-HEART: CTCA may reduce future MI risk in patients with suspected angina

Stentless bioprosthetic valve effective for patients with congenital heart disease

Monthly alirocumab may provide additional treatment option for lowering LDL

Early-onset vasomotor symptoms linked with endothelial dysfunction

Medical advice motivates patients to reduce sodium intake

LEGACY: Weight loss improves AF burden

Infants with certain congenital defects, genetic variant show better postsurgical outcomes

PARTNER 1: TAVR equivalent to surgery in high-risk patients, better than standard care in inoperable patients

OSLER: Two studies indicate long-term safety, efficacy of evolocumab for LDL reduction

Pharmacology Consult

The role of lipid-lowering therapies: A look at the guidelines

Alexander Kantorovich, PharmD, BCPS; Diana Isaacs, PharmD, BCPS, BC-ADM

Trial Scorecards

Trial Scorecard: PARTAGE

Trial Scorecard: PEGASUS-TIMI 54

Trial Scorecard: LEGACY

Trial Scorecard: CREDO-Kyoto

Trial Scorecard: PROMISE

Trial Scorecard: SCOT-HEART

Trial Scorecard: PRO VA

Trial Scorecard: CLEVER